HTB

Treatment access

Generic PrEP in France and Scotland challenges access across the UK

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

Swaziland nearly halves HIV incidence in five years

First dolutegravir-based FDC gets FDA tentative approval

WHO adds dolutegravir and PrEP to updated Essential Medicine List

Cochrane review of HCV treatment misses real issues of access to care

PrEP approved in Scotland but not in Wales

Sutezolid added to MPP as potential TB drug

AT LAST: Gay men and transgender people in England get vaccine to prevent genital warts and anal cancer – impressive pilot results

1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs

CHAI’s ARV market report shows more people than ever on ART in 2015 – and on better ART: but still some way to go

New online database for patent expiry dates in low- and middle-income countries

Global Fund is $2.6 billion short for 2017-2019: only $10.3 rather than 12.9 billion is available

Large disparities in costs of antiretrovirals between low- and middle-income countries

First generic version of dolutegravir approved by the FDA

Brazil to start using dolutegravir first-line in its national programme

Global Fund to reach US $13 billion target for 2017-2019: UK pledges up to $1.3 billion

Sub-Saharan African countries moving quickly to recommend “Treat All”

NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos

High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

Timeline for access to generic dolutegravir: what still needs to be done

Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART

South Africa takes bold step to provide HIV treatment for all

New antiretrovirals could mean savings up to US $3 billion by 2025

Countries with lower HIV prevalence have lower ART coverage

Community oppose dolutegravir and cabotegravir patents in India

MSF call for cap for MDR-TB drug costs: only 180 people use delamanid over two years

Global Fund provides Uganda with a year of drugs to meet shortages

Transgender people left behind in the fight against HIV: Only 17 out of 130 countries have transgender representatives

Mbeki shows no remorse for role in AIDS deaths

Treatment as Prevention (TasP) in the UK supports access to ART at any CD4 count

WHO 2015 guidelines: newly recommended generic ART products on the way for adults

Better generic ART for low and middle income countries: dolutegravir at US $44 a year

When Global Fund support ends: Sustainability lessons from transitions in Costa Rica, Fiji, Romania, and Bulgaria

Price of MDR TB drugs could be greatly reduced with competitive generic manufacture

Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23

CHAI’s ARV market report predicts that new drugs and formulations will drive the next major drop in treatment costs

New trade agreements threaten treatment access in Asia

Why the 5000% price hike for pyrimethamine in the US is relevant in the UK

Proposed TTIP trade agreement in Europe: Report shows European Commission’s access to medicines commitments are ‘empty gestures’

Australian doctors advice for buying generic sofosbuvir for HepC

“We will win or lose the fight against AIDS in next five years”: UNAIDS and Lancet commission report

The option for same day antiretroviral therapy on diagnosis: the future model for HIV care

New directions in the 2015 WHO ART guidelines

Large variation across countries in meeting UNAIDS 90-90-90 targets

Generic dolutegravir submitted to FDA for tentative approval

Lopinavir/ritonavir pellets tentatively approved by the FDA

Sofosbuvir access: new patent challenges to sofosbuvir

Hepatitis C drug access: Europe is the new Africa

Morocco’s acceptance of EU patent law threatens millions of lives

Global Fund releases end-2104 numbers

India rejects Gilead’s patent application for sofosbuvir

Savings to the NHS predicted from switching to generic antiretrovirals

Pill A, Pill B: simplified second-line treatment for low-income countries

UNAIDS sets 90-90-90 target for 2020 to end AIDS by 2030

No difference in overall anaemia rate with reduced dose AZT

Rationalising the paediatric antiretroviral formulary in Malawi

New ARV prescribing guidelines for London (2014)

Global update: hepatitis C treatment activism

Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed

FDA approvals of generic ARVS

Dolutegravir approved in Europe

BMS to add atazanavir to Patent Pool

Donors pledge $12 billion to Global Fund for 2014–2016: increase still short of $15 billion goal

Global Fund and UNAIDS urge Nigeria to reconsider new anti-gay law

Post navigation